China develops low-cost respiratory virus kit
This article was originally published in Clinica
A doctor at a Beijing hospital has developed a rapid, simple respiratory virus test. The pocket-sized kit uses monoclonal antibodies to differentiate eight types of influenza, parainfluenza, plasmodial and adenovirus under a standard light microscope after a two-to-three hour incubation on standard slides. The kit costs about 20 times less than a rapid fluorescence kit manufactured in the UK, writes Clinica's Chinese correspondent.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.